Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Moroose

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annual Review of Medicine|January 1, 1986
von Willebrand factor and platelet functionR Moroose, L W Hoyer
Blood|January 1, 1990
Gamma-glutamylcysteine synthetase deficiency and hemolytic anemiaE Beutler, R Moroose, L Kramer, et al.
British Journal of Cancer|April 25, 2007
In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancerA S Perry, B Loftus, R Moroose, et al.
Blood|December 15, 1990
Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three casesJ N Weitzel, J A Sadowski, B C Furie, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialA Bardia, W A Messersmith, E A Kio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialG N Hortobagyi, A Lacko, J Sohn, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annual Review of Medicine|January 1, 1986
von Willebrand factor and platelet functionR Moroose, L W Hoyer
Blood|January 1, 1990
Gamma-glutamylcysteine synthetase deficiency and hemolytic anemiaE Beutler, R Moroose, L Kramer, et al.
British Journal of Cancer|April 25, 2007
In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancerA S Perry, B Loftus, R Moroose, et al.
Blood|December 15, 1990
Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three casesJ N Weitzel, J A Sadowski, B C Furie, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialA Bardia, W A Messersmith, E A Kio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialG N Hortobagyi, A Lacko, J Sohn, et al.
Pageof 1